European Medicines Agency (EMA) Approves Bio-Thera Solutions’ BAT1706 (Avzivi®, bevacizumab), a biosimilar referencing Avastin®

Posted on by

BAT1706 is Bio-Thera Solutions’ second EMA approved product BAT1706 is Bio-Thera Solutions’ second product receiving marketing authorization from NMPA, FDA and EMA GUANGZHOU, China, July 30, 2024 /PRNewswire/ — Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.